-
1.发明公开
公开(公告)号：EP3336078A1
公开(公告)日：2018-06-20
申请号：EP17200696.7
申请日：2004-02-09
Applicant: Shenzhen Chipscreen Biosciences Ltd.
Inventor： Lu, Xian-Ping , Li, Zhibin , Xie, Aihua , Li, Boyu , Ning, Zhiqiang , Shan, Song , Deng, Tuo , Hu, Weiming , Shi, Leming
IPC: C07D213/56 , C07C233/51 , C07C237/42 , A61K31/4406 , A61K31/165 , A61P17/06 , A61P35/00
CPC classification number: C07D213/56 , A61P17/06 , A61P35/00 , C07C233/51 , C07C237/42
Abstract: The present invention is related to the preparation and pharmaceutical use of novel benzamide derivatives as defined in the specification of formula (I) as histone deacetylase inhibitors (HDACI), their preparations and the methods of using these compounds or their pharmaceutically acceptable salt in the treatment of cell proliferative diseases, e.g. cancer and psoriasis.
-
2.发明公开NAPHTHALENE CARBOXAMIDE DERIVATIVES AS INHIBITORS OF PROTEIN KINASE AND HISTONE DEACETYLASE, PREPARATION METHODS AND USES THEREOF 有权用作蛋白激酶和链霉菌酶的抑制剂的萘甲酰胺衍生物，其制备方法和用途
公开(公告)号：EP2439195A4
公开(公告)日：2012-10-31
申请号：EP10782884
申请日：2010-03-05
Applicant: SHENZHEN CHIPSCREEN BIOSCIENCES LTD
Inventor： LU XIANPING , LI ZHIBIN , SHAN SONG , YU JINDI , NING ZHIQIANG
IPC: C07D215/22 , A61K31/438 , A61K31/444 , A61K31/517 , A61P3/00 , A61P9/00 , A61P11/00 , A61P25/00 , A61P29/00 , A61P35/00 , A61P37/08 , C07D215/233 , C07D239/88 , C07D401/12
CPC classification number: C07D239/90 , C07D215/22 , C07D215/233 , C07D215/26 , C07D215/28 , C07D401/12
-
公开(公告)号：EP3196194A4
公开(公告)日：2018-05-30
申请号：EP15842179
申请日：2015-09-14
Applicant: SHENZHEN CHIPSCREEN BIOSCIENCES LTD
Inventor： LU XIANPING , YU JINDI , YANG QIANJIAO , LI ZHIBIN , PAN DESI , SHAN SONG , ZHU JIANGFEI , WANG XIANGHUI , LIU XIANGHENG , NING ZHIQIANG
IPC: C07D239/48 , A61K31/33 , A61K31/506 , A61P19/02 , A61P19/10 , A61P35/00 , C07D401/12
CPC classification number: C07D239/48 , A61K31/33 , A61K31/506 , A61P19/02 , C07D401/12
Abstract: An application of a compound having general formula (I) as JAK3 and/or JAK1 kinase and a preparation method for the compound.
-
4.发明公开Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation acivity 有权具有强效分化和抗增殖活性的新型苯甲酰胺衍生物的组蛋白脱乙酰酶抑制剂
公开(公告)号：EP2860174A2
公开(公告)日：2015-04-15
申请号：EP14166931.7
申请日：2004-02-09
Applicant: Shenzhen Chipscreen Biosciences Ltd.
Inventor： Lu, Xian-Ping , Li, Zhibin , Xie, Aihua , Li, Boyu , Ning, Zhiqiang , Shan, Song , Deng, Tuo , Hu, Weiming
IPC: C07D213/56 , C07C233/51 , C07C237/42 , A61K31/4406 , A61K31/165 , A61P17/06 , A61P35/00
CPC classification number: C07D213/56 , A61P17/06 , A61P35/00 , C07C233/51 , C07C237/42
Abstract: The present invention is related to the preparation and pharmaceutical use of novel benzamide derivatives as defined in the specification of formula (I) as histone deacetylase inhibitors (HDACI), their preparations and the methods of using these compounds or their pharmaceutically acceptable salt in the treatment of cell proliferative diseases, e.g. cancer and psoriasis.
Abstract translation: 本发明涉及如式（I）说明书中定义的新型苯甲酰胺衍生物作为组蛋白脱乙酰酶抑制剂（HDACI）的制备和药物用途，其制备方法和在治疗中使用这些化合物或其药学上可接受的盐的方法 的细胞增殖性疾病，例如 癌症和牛皮癣。
-
公开(公告)号：EP2930169B1
公开(公告)日：2018-07-18
申请号：EP12889061.3
申请日：2012-12-18
Applicant: Shenzhen Chipscreen Biosciences, Ltd.
Inventor： LU, Xianping , LI, Zhibin
IPC: C07D213/56 , C07D213/54 , C07D213/24 , C07D213/04 , A61K31/4406 , A61P35/00 , A61P35/02 , A61P17/06 , C07D213/82
CPC classification number: C07D213/82 , A61K31/4406 , C07B2200/13 , C07D213/04 , C07D213/24 , C07D213/54 , C07D213/56
Abstract: The present invention belongs to the field of pharmaceutical chemistry, and disclosed are two crystal forms of Childamide, that is, Chidamide crystal form A and Chidamide crystal form B, and the method for preparing the new crystal forms of Chidamide. The Chidamide crystal form A and Chidamide crystal form B of the present invention can be used for preparing drugs for treating diseases related to cell differentiation and proliferation.
-
Patent Agency Ranking6.发明授权Benzamide Derivative as Histone Deacetylase Inhibitor with Potent Differentiation and Anti-Proliferation Activity 有权苯甲酰胺衍生物作为具有有效分化和抗增殖活性的组蛋白脱乙酰酶抑制剂
公开(公告)号：EP2860174B1
公开(公告)日：2017-11-29
申请号：EP14166931.7
申请日：2004-02-09
Applicant: Shenzhen Chipscreen Biosciences Ltd.
Inventor： Lu, Xian-Ping , Li, Zhibin , Xie, Aihua , Li, Boyu , Ning, Zhiqiang , Shan, Song , Deng, Tuo , Hu, Weiming , Shi, Leming
IPC: C07D213/56 , C07C233/51 , C07C237/42 , A61K31/4406 , A61K31/165 , A61P17/06 , A61P35/00
CPC classification number: C07D213/56 , A61P17/06 , A61P35/00 , C07C233/51 , C07C237/42
Abstract: The present invention is related to the preparation and pharmaceutical use of novel benzamide derivatives as defined in the specification of formula (I) as histone deacetylase inhibitors (HDACI), their preparations and the methods of using these compounds or their pharmaceutically acceptable salt in the treatment of cell proliferative diseases, e.g. cancer and psoriasis.
-
7.发明授权NAPHTHALENE CARBOXAMIDE DERIVATIVES AS INHIBITORS OF PROTEIN KINASE AND HISTONE DEACETYLASE, PREPARATION METHODS AND USES THEREOF 有权NAPHTHALENCARBOXAMIDDERIVATIVE AS蛋白激酶蛋白去乙酰化酶，方法的抑制剂，因此使用
公开(公告)号：EP2439195B1
公开(公告)日：2014-07-16
申请号：EP10782884.0
申请日：2010-03-05
Applicant: Shenzhen Chipscreen Biosciences, Ltd.
Inventor： LU, Xianping , LI, Zhibin , SHAN, Song , YU, Jindi , NING, Zhiqiang
IPC: C07D215/22 , C07D215/233 , C07D239/88 , C07D401/12 , A61K31/438 , A61K31/444 , A61K31/517 , A61P3/00 , A61P9/00 , A61P11/00 , A61P25/00 , A61P29/00 , A61P35/00 , A61P37/08
CPC classification number: C07D239/90 , C07D215/22 , C07D215/233 , C07D215/26 , C07D215/28 , C07D401/12
-
8.发明公开SUBSTITUTED ARYLALCANOIC ACID DERIVATIVES AS PPAR PAN AGONISTS WITH POTENT ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC ACTIVITY 有权取代AKRYLALKANSÄURE衍生物作为PPAR PAN激动剂强血糖ENKE SANTANDER与血脂明镜降低活性
公开(公告)号：EP1569904A1
公开(公告)日：2005-09-07
申请号：EP03772525.6
申请日：2003-11-21
Applicant: Shenzhen Chipscreen Biosciences Ltd.
Inventor： LU, Xian-Ping Res. Inst. of Tsinghua University , Li, Zhibin, Res. Inst. of Tsinghua University , LIAO, Chenzhong,Res. Inst. of Tsinghua Univ. , SHI, Leming,Res. Inst. of Tsinghua University , LIU, Zhende,Res. Inst. of Tsinghua University , MA, Baoshun,Res. Inst. of Tsinghua University , NING, Zhiqiang,Res. Inst. of Tsinghua University , SHAN, Song,Res. Inst. of Tsinghua University , DENG, Tuo,Res. Inst. of Tsinghua University
IPC: C07D209/82 , C07D279/22 , C07D471/04 , A61K31/335 , A61K31/422 , A61K31/426 , A61K31/185 , A61K31/538 , A61K31/5415 , A61K31/403 , A61K31/55 , A61P1/18 , A61P3/10 , A61P3/04
CPC classification number: C07D401/12 , A61K31/185 , A61K31/335 , A61K31/403 , A61K31/422 , A61K31/426 , A61K31/538 , A61K31/5415 , A61K31/55 , C07D209/86 , C07D213/50
Abstract: Disclosed is the preparation and pharmaceutical use of substituted arylalcanoic acid derivatives of Formula I, wherein ring A, ring B, Rl, R2, R3, R4, R5, X, Alkl, Alk2, Arl, and Ar2 are as defined in the specification. These compounds, as selective agonists activating peroxisome proliferator-activated receptors (PPAR), in particularly the RXR/PPARalpha, RXR/PPARgamma, and RXRJPPARdelta heterodimers, are useful in the treatment and/or prevention of type 2 diabetes and associated metabolic syndrome such as hypertension, obesity, insulin resistance, hyperlipidemia, hyperglycemia, hypercholesterolemia, atherosclerosis, coronary artery disease, and other cardiovascular disorders with improved side effects profile commonly associated with conventional PPARgamma agonists.
-
9.发明公开Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation acivity 有权Neue Benzamidderivate als Histondeacetylaseinhibitoren mit potenter Differenzierungs- und Anti-Proliferationsaktivität
公开(公告)号：EP2860174A3
公开(公告)日：2015-07-08
申请号：EP14166931.7
申请日：2004-02-09
Applicant: Shenzhen Chipscreen Biosciences Ltd.
Inventor： Lu, Xian-Ping , Li, Zhibin , Xie, Aihua , Li, Boyu , Ning, Zhiqiang , Shan, Song , Deng, Tuo , Hu, Weiming
IPC: C07D213/56 , C07C233/51 , C07C237/42 , A61K31/4406 , A61K31/165 , A61P17/06 , A61P35/00
CPC classification number: C07D213/56 , A61P17/06 , A61P35/00 , C07C233/51 , C07C237/42
Abstract: The present invention is related to the preparation and pharmaceutical use of novel benzamide derivatives as defined in the specification of formula (I) as histone deacetylase inhibitors (HDACI), their preparations and the methods of using these compounds or their pharmaceutically acceptable salt in the treatment of cell proliferative diseases, e.g. cancer and psoriasis.
Abstract translation: 本发明涉及式（I）的说明书中所定义的新型苯甲酰胺衍生物作为组蛋白脱乙酰酶抑制剂（HDACI）的制备和药物应用，其制备方法以及在治疗中使用这些化合物或其药学上可接受的盐的方法 的细胞增殖性疾病，例如 癌症和牛皮癣。
-
10.发明授权SUBSTITUTED ARYLALCANOIC ACID DERIVATIVES AS PPAR PAN AGONISTS WITH POTENT ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC ACTIVITY 有权取代AKRYLALKANSÄURE衍生物作为PPAR PAN激动剂强血糖ENKE SANTANDER与血脂明镜降低活性
公开(公告)号：EP1569904B1
公开(公告)日：2012-01-11
申请号：EP03772525.6
申请日：2003-11-21
Applicant: Shenzhen Chipscreen Biosciences Ltd.
Inventor： LU, Xian-Ping Res. Inst. of Tsinghua University , Li, Zhibin, Res. Inst. of Tsinghua University , LIAO, Chenzhong, Res. Inst. of Tsinghua Univ. , SHI, Leming, Res. Inst. of Tsinghua University , LIU, Zhende, Res. Inst. of Tsinghua University , MA, Baoshun, Res. Inst. of Tsinghua University , NING, Zhiqiang, Res. Inst. of Tsinghua University , SHAN, Song, Res. Inst. of Tsinghua University , DENG, Tuo, Res. Inst. of Tsinghua University
IPC: C07D209/82 , C07D279/22 , C07D471/04 , A61K31/335 , A61K31/422 , A61K31/426 , A61K31/185 , A61K31/538 , A61K31/5415 , A61K31/403 , A61K31/55 , A61P3/00
CPC classification number: C07D401/12 , A61K31/185 , A61K31/335 , A61K31/403 , A61K31/422 , A61K31/426 , A61K31/538 , A61K31/5415 , A61K31/55 , C07D209/86 , C07D213/50
Abstract: Disclosed is the preparation and pharmaceutical use of substituted arylalcanoic acid derivatives of Formula I, wherein ring A, ring B, Rl, R2, R3, R4, R5, X, Alkl, Alk2, Arl, and Ar2 are as defined in the specification. These compounds, as selective agonists activating peroxisome proliferator-activated receptors (PPAR), in particularly the RXR/PPARalpha, RXR/PPARgamma, and RXRJPPARdelta heterodimers, are useful in the treatment and/or prevention of type 2 diabetes and associated metabolic syndrome such as hypertension, obesity, insulin resistance, hyperlipidemia, hyperglycemia, hypercholesterolemia, atherosclerosis, coronary artery disease, and other cardiovascular disorders with improved side effects profile commonly associated with conventional PPARgamma agonists.
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.014 seconds)
